Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.5690 -0.2994 (-34.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,751,078
Open 0.6695
Bid (Size) 0.5558 (3)
Ask (Size) 0.5740 (1)
Prev. Close 0.8684
Today's Range 0.5555 - 0.6849
52wk Range 0.4000 - 15.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. 
Via InvestorPlace

Performance

YTD
-86.74%
-86.74%
1 Month
+8.59%
+8.59%
3 Month
-49.20%
-49.20%
6 Month
-86.74%
-86.74%
1 Year
-96.05%
-96.05%

More News

Read More
Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today?
Via InvestorPlace
Ensysce Biosciences Secures $8 Million Convertible Note Financing
From Ensysce Biosciences, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Akebia Therapeutics And 20 Stocks Moving Premarket
Via Benzinga
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform
From Ensysce Biosciences, Inc.
Via AccessWire
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Via Benzinga
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Releases 2021 Annual Shareholder Letter
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
Via FinancialNewsMedia
Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
From Ensysce Biosciences, Inc.
Via AccessWire
51 Biggest Movers From Yesterday
Via Benzinga
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call
From Ensysce Biosciences, Inc.
Via AccessWire
Earnings Scheduled For March 31, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
42 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.